Kinase inhibitors for the treatment of inflammatory and autoimmune disorders

被引：39
作者：
Bhagwat, Shripad S. [1 ]
机构：
[1] Ambit Biosci, San Diego, CA 92121 USA
来源：
PURINERGIC SIGNALLING | 2009年 / 5卷 / 01期
关键词：
Kinase inhibitors; Anti-inflammatory agents; Autoimmune modulators; IKK2; inhibitors; Syk inhibitors; Lck inhibitors; JAK3; KAPPA-B KINASE; IKK-BETA INHIBITORS; POTENT; DISCOVERY; SYK; JAK3; LCK; SAR; DERIVATIVES; BMS-345541;
D O I：
10.1007/s11302-008-9117-z
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Drugs targeting inhibition of kinases for the treatment of inflammation and autoimmune disorders have become a major focus in the pharmaceutical and biotech industry. Multiple kinases from different pathways have been the targets of interest in this endeavor. This review describes some of the recent developments in the search for inhibitors of IKK2, Syk, Lck, and JAK3 kinases. It is anticipated that some of these compounds or newer inhibitors of these kinases will be approved for the treatment of rheumatoid arthritis, psoriasis, organ transplantation, and other autoimmune diseases.
引用
收藏
页码：107 / 115
页数：9
相关论文
共 50 条
[21]   Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors [J].
Qi, Baohui ;
Xu, Xingwei ;
Yang, Ying ;
He, Huan ;
Yue, Xupeng .
BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (17) :3825-3835
[22]   Benzimidazole Derivatives as Kinase Inhibitors [J].
Garuti, Laura ;
Roberti, Marinella ;
Bottegoni, Giovanni .
CURRENT MEDICINAL CHEMISTRY, 2014, 21 (20) :2284-2298
[23]   Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease [J].
Barker, Michael D. ;
Liddle, John ;
Atkinson, Francis L. ;
Wilson, David Matthew ;
Dickson, Marion C. ;
Ramirez-Molina, Cesar ;
Lewis, Huw ;
Davis, Rob P. ;
Somers, Donald O. ;
Neu, Margarete ;
Jones, Emma ;
Watson, Robert .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (21) :3458-3462
[24]   An updated research of glycogen synthase kinase-3β inhibitors: a review [J].
Liu, Shan-Kui ;
Xie, Hong-Xu ;
Ge, Yong-Xi ;
Zhang, Juan ;
Jiang, Cheng-Shi .
MONATSHEFTE FUR CHEMIE, 2021, 152 (01) :19-33
[25]   Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment [J].
Ma, Chenchen ;
Cui, Siyuan ;
Xu, Ruirong .
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (29) :4657-4686
[26]   The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease [J].
De Vries, L. C. S. ;
Wildenberg, M. E. ;
De Jonge, W. J. ;
D'Haens, G. R. .
JOURNAL OF CROHNS & COLITIS, 2017, 11 (07) :885-893
[27]   Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment [J].
Takahashi, Shinichiro .
HEMATOLOGY REPORTS, 2023, 15 (02) :331-346
[28]   Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases [J].
Cetkovic-Cvrlje, M ;
Uckun, FM .
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2004, 52 (02) :69-82
[29]   B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies [J].
Puri, Kamal D. ;
Di Paolo, Julie A. ;
Gold, Michael R. .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2013, 32 (04) :397-427
[30]   Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases [J].
Zhou, Yaqi ;
Zhang, Yaowen ;
Yu, Wei ;
Qin, Yufen ;
He, Heng ;
Dai, Fengxian ;
Wang, Yibo ;
Zhu, Fengqin ;
Zhou, Guangxi .
IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (07)
12345